Affinage mechanistic annotation for APLN (human) Affinage Affinage (Claude Sonnet reading pass + Opus synthesis pass) 31 citations

Affinage mechanistic annotation for APLN (human)

Current model (mechanistic narrative)

Apelin (APLN) is a secreted peptide hormone, processed from a precursor into multiple bioactive forms (apelin-13, apelin-17, apelin-36), that acts as an endogenous agonist of the G-protein-coupled apelin receptor APJ/APLNR to coordinate cardiovascular, angiogenic, metabolic, and tissue-protective programs PMID:15907343. Engagement of APJ activates Gαi2/Gαi3 by molecular rearrangement and Gαo/Gαq by classical dissociation PMID:25193074, driving PI3K/Akt and MAPK/ERK signaling that underlies its cellular effects, including cardioprotection against ischemia-reperfusion injury via the RISK pathway and delay of mitochondrial permeability transition pore opening PMID:17694254. Receptor activation is followed by GRK2-mediated, β-arrestin1-independent, clathrin/dynamin-dependent internalization, and downstream signaling bias is encoded structurally: the I109^3.32 residue of TM3 controls the balance between G protein and β-arrestin/GRK recruitment [PMID:30409826, PMID:27492965], and structure-guided design of G-protein-biased agonists yields improved efficacy against cardiac hypertrophy PMID:38428423. Crystal and cryo-EM structures defined a curved two-site peptide binding mode and stoichiometry-dependent G protein coupling, and showed that the second endogenous ligand Elabela/Toddler engages APJ through a distinct binding mode from apelin [PMID:28528775, PMID:35817871, PMID:32301550]. APLN is transcriptionally induced by hypoxia through HIF-1α binding to an intronic hypoxia-responsive element PMID:18617693, by β-catenin in hepatocellular carcinoma PMID:31410213, and by muscle contraction as an exerkine PMID:30061698. Functionally, apelin marks and drives sprouting (tip) endothelial cells in angiogenesis PMID:25597280, promotes lymphangiogenesis PMID:24962866, directs cardiac precursor migration during gastrulation PMID:17336905, enhances muscle mitochondriogenesis and autophagy PMID:30061698, and protects vasculature against aneurysm and oxidative injury [PMID:31189595, PMID:32879139]; its peptides are inactivated by ACE2 and by neutral endopeptidase [PMID:15907343, PMID:31189595]. The APLN/APJ axis also regulates Sertoli-cell carnitine production and blood-testis barrier integrity PMID:36443325 and cholangiocyte proliferation through Nox4/ROS/ERK signaling PMID:32964473, and apelin inhibition reduces tumor angiogenesis and glioblastoma stem-like cell expansion [PMID:31267692, PMID:29053791].

Affinage mechanism profile (Affinage's own GO/Reactome grounding)

Dated findings (citation-anchored)

Year Confidence Finding PMIDs Journal
2005 High Apelin peptides are derived from a single gene and activate the 7-transmembrane G-protein-coupled receptor APJ; apelin peptides also represent substrates for ACE2 carboxypeptidase, which cleaves and inactivates them. PMID:15907343 Pharmacology & therapeutics
2008 High Hypoxia induces apelin expression in endothelial and vascular smooth muscle cells via HIF-1α binding to a hypoxia-responsive element (HRE) located within the first intron (+813/+826) of the human apelin gene; siRNA knockdown of HIF-1α abolished hypoxia-induced apelin expression; apelin or APJ receptor knockdown inhibited hypoxia-induced endothelial cell proliferation in vitro and vessel regeneration in zebrafish. PMID:18617693 Circulation research
2007 High Apelin-13 and apelin-36 produce cardioprotection against ischemia-reperfusion injury by activating the PI3K-Akt and p44/42 MAPK (RISK pathway) and delaying mitochondrial permeability transition pore (MPTP) opening; pharmacological inhibition of PI3K (LY294002) or MEK (UO126/MEK inhibitor 1) abolished the protective effects. PMID:17694254 Basic research in cardiology
2007 High Zebrafish apelin (ligand) and its receptor Agtrl1b (APJ homolog) control heart field formation during gastrulation by directing convergence of cardiac precursors from lateral plate mesoderm toward the midline; reduced or excess Apelin/Agtrl1b function caused deficiency of cardiac precursors and heart defects. PMID:17336905 Developmental cell
2015 Medium Apelin-APJ signaling promotes brown adipocyte differentiation and browning of white adipocytes by increasing expression of brown adipogenic and thermogenic transcription factors via PI3K/Akt and AMPK signaling pathways; apelin also increases mitochondrial biogenesis, PGC1α and UCP1 expression, and oxygen consumption. PMID:25931124 The Journal of biological chemistry
2015 High APLN is robustly expressed in sprouting (tip) endothelial cells during angiogenesis and is re-activated in adult endothelial cells after ischemia; genetic ablation using Apln-CreER specifically labels sprouting but not quiescent vasculature, and abolishment of VEGF-VEGFR2 signaling reduced APLN expression in sprouting endothelium. PMID:25597280 Nature communications
2015 High Elabela (ELA)/Toddler activates the apelin receptor (APJ) in mammalian cells, causing receptor internalization, suppression of cAMP production (EC50 ~11 nM), ERK1/2 phosphorylation (EC50 ~14 nM), and weak intracellular calcium mobilization; ELA also induces angiogenesis in endothelial cells and relaxes mouse aortic blood vessels. PMID:25639753 Scientific reports
2017 High Crystal structure of human apelin receptor (APJR) at 2.6 Å resolution in complex with a 17-amino acid apelin mimetic peptide revealed a lactam-constrained, curved two-site ligand binding mode; mutation analysis and molecular dynamics simulations with apelin-13 identified key binding residues for apelin recognition and specificity. PMID:28528775 Structure
2016 High Apelin-induced internalization of APJ occurs via clathrin-coated vesicles (CCVs) in a GRK2-mediated phosphorylation-dependent, β-arrestin1-independent, EPS15- and dynamin-dependent manner; [Pyr1]apelin-13 stimulation also causes rapid desensitization of APJ-mediated ERK1/2 (ppERK1/2) signaling through upstream APJ-specific adaptive changes rather than internalization. PMID:27492965 Molecular and cellular endocrinology
2014 Medium Apelin-13 stimulation of APJ activates Gαi2 and Gαi3 through molecular rearrangement (rather than classical dissociation), while Gαo and Gαq are activated through classical dissociation; Gαi1 showed little change after apelin-13 stimulation. PMID:25193074 Experimental cell research
2006 Medium Apelin and APJ are expressed in human osteoblasts; apelin stimulates osteoblast proliferation via APJ-dependent activation of PI3K/Akt (but not JNK, p38, or ERK1/2); siRNA-mediated APJ knockdown and LY294002 (PI3K inhibitor) abolished apelin-induced proliferation. PMID:16563531 Regulatory peptides
2018 Medium Apelin inhibition reduces tumor angiogenesis, remodels the tumor microenvironment by reducing polymorphonuclear myeloid-derived suppressor cell infiltration, and prevents resistance to anti-angiogenic RTK inhibitor therapy; apelin loss alone accelerated tumor cell invasion, but combined apelin/VEGFR2 blockade was synergistically effective. PMID:31267692 EMBO molecular medicine
2019 Medium APLN is transcriptionally upregulated by active β-catenin, which binds to the APLN promoter to induce transcription in hepatocellular carcinoma; APLN activates PI3K/Akt via APLN receptor, leading to increased p-GSK3β and cyclin D1, promoting G1/S cell cycle progression and inhibiting apoptosis. PMID:31410213 Theranostics
2019 High APLN protects against abdominal aortic aneurysm by preventing smooth muscle cell apoptosis and oxidative stress; APLN induces ACE2 expression in the vasculature; neutral endopeptidase (NEP) is a major enzyme that metabolizes and inactivates APLN-17 in human AAA tissue; a NEP-resistant APLN-17 analog (APLN-NMeLeu9-A2) ameliorated Ang II-mediated AAA in mice. PMID:31189595 Proceedings of the National Academy of Sciences of the United States of America
2022 High Cryo-EM structures of fully active human apelin receptor (APJR) complexed with heterotrimeric G protein in both 2:1 (dimer:G protein) and 1:1 (monomer:G protein) stoichiometric ratios were determined; structural differences in G protein engagement between dimeric and monomeric APJR suggest a role for stoichiometry in GPCR-G protein coupling and downstream signaling; a small hydrophobic dimer interface was identified. PMID:35817871 Nature structural & molecular biology
2018 High A single residue mutation I109A (I109^3.32) in transmembrane domain 3 of APJ converts a balanced receptor into a G protein-biased receptor: it retains full ligand binding and G protein activation but is defective in GRK recruitment, β-arrestin recruitment, and downstream receptor-mediated ERK activation; molecular dynamics simulations indicated that the Phe-13 residue of apelin rotates to form new hydrophobic interactions with TM3 residues (F110, M113), stabilizing the biased conformation. PMID:30409826 The Biochemical journal
2024 High Cryo-EM structures of APLNR-Gi1 complexes bound to three agonists with divergent signaling profiles identified 'twin hotspots' in APLNR as key determinants for G protein vs. β-arrestin signaling bias; structure-guided design produced G protein-biased agonists WN353 and WN561, which showed superior therapeutic effects against cardiac hypertrophy with reduced adverse effects compared to established APLNR agonists. PMID:38428423 Cell
2021 High APLN is produced by Sertoli cells in response to high glucose, and hyper-activated APLN/APJ signaling in diabetic testes suppresses carnitine production and represses cell adhesion gene expression in Sertoli cells, causing blood-testis barrier (BTB) structural dysfunction and impaired spermatogenesis; pharmacological blockade of APLN/APJ with ML221 ameliorated BTB damage and improved spermatogenesis in diabetic db/db mice and cultured human testes. PMID:36443325 Nature communications
2021 High Apelin induces cholangiocyte proliferation through Nox4/ROS/ERK-dependent signaling and activates hepatic stellate cells (HSCs) through intracellular ROS; APLN knockout or APJ antagonism (ML221) reduced bile duct ligation-induced cholangiocyte proliferation, liver inflammation, fibrosis, and angiogenesis in mice. PMID:32964473 Hepatology
2020 High Elabela/Toddler and apelin bind differently to the apelin receptor: alanine scanning of ELA showed the C-terminus carries the key pharmacophore; Asp282/Asp284 of rat/human apelin receptor are critical for apelin binding and activity but are NOT involved in Elabela/Toddler activity, demonstrating distinct binding modes for the two endogenous ligands. PMID:32301550 FASEB journal
2021 Medium Apelin-13, pGlu1-apelin-13, apelin-17, apelin-36, Elabela-21, and Elabela-32 exhibit distinct signaling profiles at APJ: all activate both G protein-dependent (cAMP inhibition, Ca2+ mobilization, early-phase ERK activation) and β-arrestin-dependent (GRKs, β-arrestin 1/2, AP2) pathways in a dose-dependent manner, but with different bias ratios; Elabela-32 showed >1000-fold bias to β-arrestin-dependent signaling, and apelin-17 was biased toward β-arrestin-dependent signaling. PMID:33746758 Frontiers in pharmacology
2017 High Protamine binds the apelin receptor (APJ) with 390 nM affinity and acts as a full antagonist of both G protein and β-arrestin-dependent intracellular signaling; ex vivo and in vivo, protamine abolishes apelin-mediated angiogenesis, glucose tolerance improvement, and vasodilatation; protamine's APJ antagonist activity is fully reversed by heparin both in vitro and in vivo. PMID:28242772 FASEB journal
2016 Medium Apelin (APLN-13 and APLN-17) increases steroidogenesis (basal and IGF1-induced progesterone and estradiol) in human luteinized granulosa cells through activation of AKT and MAPK3/1 (ERK1/2) pathways and increased HSD3B protein expression; these effects are reversed by the APLNR antagonist ML221. PMID:27683264 Biology of reproduction
2017 Medium In bovine granulosa cells, APLN-13 and APLN-17 increase progesterone production via MAPK ERK1/2 and increase cell proliferation via AKT signaling (blocked by ML221); conversely, APLN-13 and APLN-17 arrest bovine oocytes at germinal vesicle stage during in vitro maturation, associated with decreased progesterone, inhibited ERK1/2 phosphorylation, and increased PRKA phosphorylation. PMID:28250234 Reproduction
2018 Medium Apelin promotes lymphangiogenesis: APJ is expressed in lymphatic endothelial cells (LECs) and activates apelinergic signaling; apelin treatment enhances LEC migration, protects against UV-induced apoptosis, increases spheroid formation, stimulates in vitro tube formation, and promotes in vivo lymphatic microvessel invasion; apelin overexpression in tumor cells increases intratumoral lymphangiogenesis and lymph node metastasis. PMID:24962866 Oncotarget
2018 High Apelin deficiency in mice increases NADPH-stimulated superoxide levels in atria and slows atrial conduction velocities; apelin administration in mice with increased AF vulnerability reduced AF incidence/duration, prolonged atrial refractory periods, accelerated conduction velocity, and increased action potential duration; these electrophysiological effects were associated with increased atrial cardiomyocyte sodium currents. PMID:32879139 JCI insight
2018 High The exerkine apelin is induced by muscle contraction; apelin or APLNR deficiency in mice causes age-dependent muscle dysfunction; restoration of apelin signaling enhances muscle function by triggering mitochondriogenesis, autophagy, and anti-inflammatory pathways in myofibers, and enhances regenerative capacity by targeting muscle stem cells. PMID:30061698 Nature medicine
2015 Medium Apelin controls fetal glucose homeostasis: intravenous apelin injection in pregnant rats increases transplacental glucose transport; intraperitoneal apelin in neonates increases glucose uptake in lung and muscle; the apelinergic system is expressed at the fetoplacental interface and in multiple fetal tissues; placenta releases high amounts of apelin in late gestation ex vivo. PMID:26631739 Diabetes
2017 Medium APJ is expressed at cellular junctions in human umbilical vein endothelial cells (HUVECs) and may associate with PECAM-1; siRNA-mediated silencing of APJ influences shear-induced cytoskeletal remodeling, cellular elasticity, motility, attachment, and distribution of adhesion complexes in endothelial cells. PMID:29369349 Journal of cellular physiology
2021 Medium Apelin improves endothelial cell dysfunction in diabetes by decreasing apoptosis, reducing adhesion molecule expression, and increasing proliferation, angiogenesis, and expression of E-cadherin, VEGFR2, and Tie-2; these effects were dependent on APJ and downstream NF-κB pathways, as confirmed by endothelial cell-specific APJ knockout mice. PMID:33504680 The Journal of endocrinology
2017 Medium Apelin is identified as a factor secreted by brain endothelial cells (by mass spectrometry proteomics) that maintains glioblastoma stem-like cell expansion; genetic and pharmacological targeting of the apelin receptor abrogates apelin- and endothelial-mediated expansion of glioblastoma stem-like cells in vitro and suppresses tumor growth in vivo. PMID:29053791 Brain

Citations